CEL-SCI'S MULTIKINE SHOWN TO INCREASE SURVIVAL IN CANCER PATIENTS

CEL-SCI has announced positive results from a long-term follow-up study of head and neck cancer patients treated with its drug Multikine in a Phase II clinical trial. The follow-up study indicated that Multikine treatment resulted in a substantial increase in the survival of patients.

The study, which used the same Multikine treatment protocol as proposed for the Phase III trial, included advanced primary head and neck cancer patients who were scheduled for their first cancer treatment. The Multikine treatment was administered for 3 weeks prior to the standard treatment for head and neck cancer, surgery or surgery plus radiation/chemotherapy. Results from this study were published in the Journal of Clinical Oncology.